Today's episode dives into the recent chatter surrounding the off-label use of Semaglutides such as Wegovy and Ozempic as weight loss aids. We discuss the mechanism and function of these medications, the latest evidence on potential risk, and the need to make informed decisions and consider long term sustainability.

3:10 We talk through the history of weight loss medications and diet pills back to the victorian era, from tapeworms to arsenic pills. The marketing of quick diet solutions has almost always preyed on insecurities and pushing individuals to conform to societal beauty standards.

8:38 Originally approved by the FDA for the treatment of Type 2 Diabetes, these GLP-1 agonists have recently gained popularity for off-label use as weight loss aids. By stimulating insulin production and promoting feelings of fullness, these drugs can act as appetite suppressants for non-diabetic individuals.

13:00 We note the popular “Ozempic Effect” and current role of influencers in popularity of Semaglutides.

14:30 Despite their potential benefits, the off-label use of Semaglutides has raised a number of concerns. The co-opting of these drugs as weight loss tools could limit their availability to those who need them for diabetes management. When used off-label, a major function of GLP-1 agonists is promoting satiety, making it difficult to eat.

17:36 There's also a lack of research on their long-term impacts, and they could pose risks such as muscle loss and an array of side effects, including nausea, vomiting, dizziness, infections, and headaches. We talk through the lack of knowledge on long term effects and findings from the STEP trial. Many findings show that weight regain after stopping Semaglutides is significant.

21:05 We discuss the potential impact of semaglutides on muscle wasting/loss of muscle mass and how more research is needed in this area.

23:02 We look at the more modern history of weight loss drugs, which has seen its share of 'miracle solutions' turn into dangerous hazards. Remember the Phen-Fen debacle of the '90s? It serves as a potent reminder of how quickly things can go wrong when long-term effects aren't fully understood.

29:07 We share our personal opinions on whether or not there is a place for GLP-1 agonists in off-label use and who can potentially benefit from these medications.

34:03 Semaglutides don't address the need for habit building, a critical component of sustainable weight loss. Developing healthy behaviors, like regular exercise and mindful eating, are key for long-term success.

40:34 There is information to consider and there are questions we can ask ourselves regarding Semaglutide injection use when it comes to making the most informed decision possible.

💛 STAY CONNECTED
Don’t forget to subscribe to our podcast so you never miss an episode.

🟡 Michael Ulloa
Website: michaelulloa.com
Instagram: @michaelulloapt

🟡 Kate Lyman
Website: katelymannutrition.com
Instagram: @klnutrition

Thank you for listening to the How to: Fitness Podcast with Michael Ulloa and Kate Lyman!